Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Kezar Life Sciences, Inc. (KZR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Investor Contact:"
05/11/2023 8-K Quarterly results
Docs: "Investor Contact:"
11/10/2022 8-K Quarterly results
Docs: "Investor Contact:"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update • Topline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022 • Zetomipzomib assigned as nonproprietary name for lead candidate, KZR-616 • Cash, cash equivalents and marketable securities totaled $208.4 million as of year-end 2021 SOUTH SAN FRANCISCO, Calif. – – March 17, 2022 – Kezar Life Sciences, Inc., , a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. “In 2021, we made significant progress in each of our programs, achieving target enrollmen..."
11/09/2021 8-K Quarterly results
Docs: "Kezar Reports Third Quarter Financial Results and Provides Business Update"
08/12/2021 8-K Quarterly results
Docs: "Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates"
11/05/2020 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $150.0 million as of September 30, 2020, compared to $78.2 million as of December 31, 2019. The increase in cash, cash equivalents and marketable securities was primarily attributable to the net proceeds from Kezar’s underwritten public offerings in February and June 2020, net of cash used by the Company in operations to advance its clinical stage programs and preclinical research and development. • Research and development expenses for the third quarter of 2020 increased by $1.2 million to $8.3 million, compared to $7.1 million in the third quarter of 2019. This increase was primarily related to advancing both the KZR-616 clinical program in multiple indications and the protein secretion preclinical program. • General ..."
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $123.4 million as of March 31, 2020, compared to $78.2 million as of December 31, 2019. The increase in cash, cash equivalents and marketable securities was primarily attributable to the net proceeds from the underwritten public offering in February 2020, net of cash used by the Company in operations to advance its clinical stage programs and preclinical research and development. The Company believes that its current cash, cash equivalent and marketable securities are sufficient to fund planned operations into the third quarter of 2022. • Research and development expenses for the first quarter of 2020 increased by $1.6 million to $7.5 million, compared to $5.9 million in the first quarter of 2019. This increase was primarily r..."
11/06/2019 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $85.2 million as of September 30, 2019, compared to $107.4 million as of December 31, 2018. The decrease in cash, cash equivalents and marketable securities was primarily attributable to cash used by the company in operations to advance its clinical stage programs as well as preclinical research and development. • Research and development expenses for the third quarter of 2019 increased by $2.4 million to $7.1 million compared to $4.7 million in the third quarter of 2018. This increase was primarily related to advancing both the KZR-616 clinical program in multiple indications and the protein secretion preclinical program. • General and administrative expenses for the third quarter of 2019 increased by $1.0 million to $..."
08/07/2019 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $93.4 million as of June 30, 2019, compared to $107.4 million as of December 31, 2018. The decrease in cash, cash equivalents and marketable securities was primarily attributable to cash used by the company in operations to advance its clinical stage programs as well as preclinical research and development. • Research and development expenses for the second quarter of 2019 increased by $1.7 million to $6.9 million from $5.2 million in the second quarter of 2018. This increase was primarily related to advancing both the KZR-616 clinical program across indications and the protein secretion preclinical program. • General and administrative expenses for the second quarter of 2019 increased by $0.7 million to $2.4 million fr..."
05/07/2019 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $101.1 million as of March 31, 2019, compared to $107.4 million as of December 31, 2018. The decrease in cash, cash equivalents and marketable securities was primarily attributable to cash used by the Company in operations to advance its clinical stage programs as well as preclinical research and development. • Research and development expenses for the first quarter of 2019 increased by $2.3 million to $5.9 million from $3.6 million in the first quarter of 2018. This increase was primarily related to advancing both the KZR-616 clinical program across indications and the protein secretion preclinical program. • General and administrative expenses for the first quarter of 2019 increased by $0.9 million to $2.4 million fro..."
03/26/2019 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $107.4 million as of December 31, 2018, compared to $51.0 million as of December 31, 2017. The increase in cash, cash equivalents and marketable securities was primarily attributable to IPO proceeds, net of cash used by the Company in operations to advance its clinical stage programs as well as preclinical research and development. • Research and development expenses for the fourth quarter of 2018 increased by $3.0 million to $4.6 million from $1.6 million in the fourth quarter of 2017. Full year R&D expenses increased by $11.7 million in 2018 compared to 2017. This increase was primarily related to advancing both the KZR-616 clinical program across indications and the protein secretion preclinical program in addition to perso..."
11/08/2018 8-K Quarterly results
Docs: "Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017"
08/09/2018 8-K Quarterly results
Docs: "Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy